Theratechnologies (NASDAQ:THTX) Rating Lowered to “Hold” at Jones Trading

Theratechnologies (NASDAQ:THTXGet Free Report) was downgraded by equities research analysts at Jones Trading from a “strong-buy” rating to a “hold” rating in a research note issued on Thursday, MarketBeat.com reports.

Theratechnologies Trading Up 32.6%

Theratechnologies stock opened at $3.13 on Thursday. The stock has a market cap of $143.92 million, a P/E ratio of -39.13 and a beta of 0.55. The stock has a 50 day moving average of $2.61 and a 200-day moving average of $2.06. Theratechnologies has a 52 week low of $1.12 and a 52 week high of $3.20.

Hedge Funds Weigh In On Theratechnologies

Several institutional investors and hedge funds have recently made changes to their positions in THTX. Raymond James Financial Inc. purchased a new position in shares of Theratechnologies during the 4th quarter valued at approximately $27,000. Harbour Investments Inc. lifted its stake in Theratechnologies by 20.0% during the fourth quarter. Harbour Investments Inc. now owns 87,772 shares of the company’s stock worth $159,000 after purchasing an additional 14,655 shares during the last quarter. Virtu Financial LLC bought a new position in Theratechnologies during the fourth quarter worth $40,000. Hillsdale Investment Management Inc. bought a new position in Theratechnologies during the fourth quarter worth $108,000. Finally, JPMorgan Chase & Co. bought a new position in Theratechnologies during the fourth quarter worth $33,000.

About Theratechnologies

(Get Free Report)

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.

Read More

Receive News & Ratings for Theratechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies and related companies with MarketBeat.com's FREE daily email newsletter.